Wyeth Pharmaceuticals has launched pristiq (desvenlafaxine), a new serotonin-norepinephrine reuptake inhibitor (SNRI) in US market.

Wyeth Pharmaceuticals has launched pristiq (desvenlafaxine), a new serotonin-norepinephrine reuptake inhibitor (SNRI) in US market.

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, haemophilia, oncology, vaccines and nutritional products. 

Pristiq (desvenlafaxine), a new serotonin-norepinephrine reuptake inhibitor (SNRI) is  approved to treat adult patients with major depressive disorder (MDD). The recommended dose of Pristiq is 50 milligrams (mg) once daily.
The most commonly observed adverse reactions in patients taking Pristiq for MDD in short-term, fixed-dose studies (incidence > 5 per cent and at least twice the rate of placebo in the 50 mg dose groups) were nausea, dizziness, hyperhidrosis, constipation and decreased appetite.